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There is general consensus that consensus guidelines for
care standards are an important tool to provide both
healthcare professionals and the patient community
with up to date information about all aspects of best
practices in a specific disease area. The specific develop-
ment of care guidelines for neuromuscular diseases
poses a number of challenges. All neuromuscular dis-
eases are rare and many show a broad spectrum of clini-
cal and genetic heterogeneity. A paucity of randomized
controlled trials for most conditions means that best-
practice care guidelines are often non-existent or poorly
developed. Where they exist, healthcare professionals
may be unaware of them. In many cases the lack of care
guidelines contributes to a lack of clinical trial activity,
as the implementation of care guidelines is also a prere-
quisite for a reliable comparison of outcome measures
in clinical trials, especially in the neuromuscular disease
field, where trials are normally multi-centric and inter-
national. Over the past years there have been various
collaborative efforts to achieve trial readiness for a num-
ber of neuromuscular diseases by establishing care
guidelines, patient registries and networks of care and
trial sites. For some of the most common neuromuscu-
lar diseases like spinal muscular atrophy (SMA) and
Duchenne muscular dystrophy (DMD) there are now
international care guidelines for healthcare professionals
and patients and families. Key factors that have helped to
establish these care guidelines were the involvement of
patient organizations, translational research networks,
and health agencies and combining existing evidence
with consensus among a large number of experts in dif-
ferent care areas. Once care guidelines have been estab-
lished, it is important to disseminate them to the
stakeholder community through clinics, meetings, journal
and website publications, media interviews, patient regis-
tries and professional training courses. It is also crucial to
keep care guidelines updated and to take new therapeutic
developments and health research outcomes into
account. Once care guidelines have been agreed and dis-
seminated, it then becomes important to monitor their
implementation and to assess whether they do indeed
have a positive impact on health. This is particularly
important for guidelines that are based on expert opi-
nions that lack higher levels of evidence. Finally, we need
to better understand why, despite agreed upon care
guidelines for various neuromuscular diseases, many
patients do not receive the treatment they describe.
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